Platinum Resistant Epithelial Ovarian Cancer Type II
1 clinical trials · Condition
◉ Watch Platinum Resistant Epithelial Ovarian Cancer Type II
| Record | Firm | Date |
|---|---|---|
| Study of Azacitidine and Durvalumab in Advanced Solid Tumors (NCT02811497) | University Health Network, Toronto | 2016-09-01 |
Track Platinum Resistant Epithelial Ovarian Cancer Type II automatically
Every clearance here is in the API, with alerts when new ones post.